Promising results of a multi-center clinical trial evaluating Cognoptix's (Acton, Massachusetts) Sapphire II eye test could bring the firm one step closer to having an approved application to identify Alzheimer's disease. Results of the trial were published in the latest issue of the Journal of Alzheimer's Disease & Other Dementias.
Read More
